Abstract
Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic((R))), a modified human glucagon-like peptide-1 (GLP-1) analogue, for th......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
